[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"norm-eurlex-reg_2016_1902-erwgr-12-de":3},{"law":4,"norm_id":14,"norm_key":15,"slug":16,"title":17,"chapter":18,"content":19,"enriched_content":20,"hierarchy":21,"neighbors_before":22,"neighbors_after":32,"citing_decisions":42,"is_thin":43},{"abbreviation":5,"title":6,"source_type":7,"jurisdiction":8,"document_kind":9,"language":10,"attribution":11,"version_date":12,"source_url":13},"reg_2016_1902","zur Änderung der Anhänge II und III der Verordnung (EG) Nr. 396\u002F2005 des Europäischen Parlaments und des Rates hinsichtlich der Höchstgehalte an Rückständen von Acetamiprid, Ametoctradin, Azoxystrobin, Cyfluthrin, Difluoressigsäure, Dimethomorph, Fenpyrazamin, Flonicamid, Fluazinam, Fludioxonil, Flupyradifuron, Flutriafol, Fluxapyroxad, Metconazol, Proquinazid, Prothioconazol, Pyriproxyfen, Spirodiclofen und Trifloxystrobin in oder auf bestimmten Erzeugnissen","eurlex","eu","regulation","de","© Europäische Union, https:\u002F\u002Feur-lex.europa.eu","2025-02-06","https:\u002F\u002Feur-lex.europa.eu\u002Flegal-content\u002FDE\u002FALL\u002F?uri=CELEX:32016R1902",7077887,"ErwGr. 12","erwgr-12",null,"Erwägungsgründe","Die Verordnung (EG) Nr. 396\u002F2005 sollte daher entsprechend geändert werden.","REG_2016_1902 - Erwägungsgründe - ErwGr. 12\n\nDie Verordnung (EG) Nr. 396\u002F2005 sollte daher entsprechend geändert werden.",{},[23,26,29],{"norm_key":24,"title":17,"slug":25},"ErwGr. 11","erwgr-11",{"norm_key":27,"title":17,"slug":28},"ErwGr. 10","erwgr-10",{"norm_key":30,"title":17,"slug":31},"ErwGr. 9","erwgr-9",[33,36,39],{"norm_key":34,"title":17,"slug":35},"ErwGr. 13","erwgr-13",{"norm_key":37,"title":17,"slug":38},"Art. 1","art-1",{"norm_key":40,"title":17,"slug":41},"Art. 2","art-2",[],true]